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Objectives This study sought to evaluate the effect of intensive and moderate statin therapy on epicardial adipose tissue (EAT).
Background EAT has been associated with coronary artery disease severity and outcome. It is currently unknown whether
EAT volume changes over time when patients are exposed to statin therapy.
Methods Subanalysis of a randomized study of atorvastatin 80 mg/day versus pravastatin 40 mg/day for 1 year in a clini-
cal trial designed to assess the progression of coronary artery calcium (CAC) in hyperlipidemic post-menopausal
women. Patients underwent cardiac computed tomography scans at the start and end of the trial period.
Results Of 420 patients, 194 received atorvastatin and 226 pravastatin; the median low-density lipoprotein change was
53.3% and 28.3% with atorvastatin and pravastatin, respectively (p  0.001). Baseline EAT correlated with
age, body mass index, hypertension, diabetes mellitus, high-density lipoprotein, triglyceride levels, and CAC (p 
0.001). At the end of follow-up, EAT regressed more in the atorvastatin than in the pravastatin group (median,
3.38% vs. 0.83%, p  0.025). The EAT percent change from baseline was significant in the atorvastatin, but
not the pravastatin group (p  0.001 and p  0.2, respectively). There was no correlation between lipid lowering
and EAT regression. CAC progressed significantly in both groups from baseline.
Conclusions In hyperlipidemic post-menopausal women, statin therapy induced EAT regression, although intensive therapy
was more effective than moderate-intensity therapy. This effect does not seem linked to low-density lipopro-
tein lowering and may be secondary to other actions of statins such as anti-inflammatory effects. (J Am
Coll Cardiol 2013;61:1956–61) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.051Epicardial adipose tissue (EAT) is a novel marker of coronary
atherosclerosis risk and is believed to participate in the pathogen-
esis of coronary plaque formation through a paracrine effect (1,2).
It is associated not only with the presence of but also with some
features of vulnerability of atherosclerotic plaques (3–5).
Intensive lipid-lowering therapy with statins has been
shown to halt the progression of atherosclerosis (6). We
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10, 2012; accepted December 16, 2012.previously reported the effect of intensive versus moderate
lipid-lowering therapy on coronary artery calcium (CAC) in
a randomized trial of hyperlipidemic post-menopausal
women and described the progression of CAC in both study
arms with no significant difference between treatments (7).
See page 1962
In the current analysis, we sought to investigate the effect of
intensive versus moderate lipid-lowering therapy on EAT in
the same population.
Methods
Study population. The study protocol was previously de-
scribed in detail (7) and is summarized briefly here. The
BELLES (Beyond Endorsed Lipid Lowering with Electron
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demic post-menopausal women to study the effect of moderate
ersus aggressive lipid-lowering treatment with statins on the
rogression of CAC, and 475 of the patients enrolled completed
he study. For the purpose of the current analyses, we reviewed all
vailable chest computed tomography (CT) scans of adequate
uality to measure EAT. Thus, the study population consisted of
20 women with either surgically induced or spontaneous
enopause, and serum levels of low-density lipoprotein (LDL)
130 mg/dl if they had known coronary heart disease or a 10-year
ramingham risk score 10%; the serum LDL level at enroll-
ent could be160 mg/dl if the 10-year Framingham risk score
as 10% (7). Of the original 475 patients, 55 patients were
xcluded from these analyses because of an error that occurred
t the time the CT images were stored in DICOM format; this
rror rendered the interpretation of the images impossible. The
linical characteristics of the 55 excluded patients were identi-
al to those of the 420 patients included in these analyses.
Patients underwent an initial screening visit, which in-
luded an assessment of their medical history, coronary
eart disease risk profile, and laboratory testing. If they met
he inclusion/exclusion criteria, they were then eligible to
ndergo the baseline chest CT scan and be randomized.
atients were randomized to a double-blind treatment with
ither atorvastatin 80 mg/day and matching pravastatin
lacebo or pravastatin 40 mg/day and matching atorvastatin
lacebo, all taken at bedtime. A follow-up CT scan was
cheduled at 12 months after randomization. The study was
pproved by the review committee of each participating
nstitution, and the subjects gave informed consent to
articipate.
T imaging for CAC and EAT assessment. Electron
eam CT scanning was performed with C-150 Imatron
canners (GE Imatron, San Francisco, California). Both
aseline and follow-up scans were performed using a stan-
ard imaging protocol, as previously described (7). A total
f 36 to 40 slices spanning from the carina to the dia-
hragm, 3-mm thick, were obtained during a single breath
old. A calcified coronary plaque was considered present if
t least 3 contiguous pixels with a minimal attenuation of
30 Hounsfield units were detected along the course of the
oronary artery tree and the calcium volume score (CVS)
as calculated as previously described (8).
The EAT volume was measured on the same axial images
s those used for CAC scoring (Fig. 1), using the Volume
nalysis software of a Leonardo workstation (Siemens,
rlangen, Germany), as previously described (9). All slices
rom the bifurcation of the pulmonary artery to the dia-
hragm were used for the analyses. The region of interest
ontaining the heart and the surrounding EAT was assessed
y manually tracing the epicardium in the axial slices; a
hreshold of 190 to 30 HU units was then applied to
solate the fat-containing voxels. The fat voxels were
ummed to obtain the total EAT volume in milliliters. All
easurements were made by 3 experienced investigatorslinded to the patients’ treatment and all other clinical data, asreviously described (3,9). A ran-
om sample of 50 patient scans
as selected for the 3 investigators
o perform repeat, blinded read-
ngs. This allowed the calculation
f intra- and inter-reader repeat-
bility of EAT measurements.
he average intrareader variability
or all investigators was 1% (be-
ween 0.6% and 0.8%), represent-
ng a high degree of reliability in
he repeat measurements.
tatistical analysis. Continuous
ariables are presented as median
nd range, whereas categorical
ariables are presented as fre-
uencies and percentages. The
ariables CAC, EAT, total cholesterol, triglycerides, HDL,
nd LDL had 2 data points (baseline and final) for each
ubject. The percent change between 2 data points for each
ndividual parameter in each subject was calculated as (final 
aseline)/baseline · 100 and used for the analysis. Non-HDL
cholesterol was calculated as total cholesterol  HDL.
ilcoxon rank sum test was used to compare the percent
hange of CVS, EAT, total cholesterol, triglycerides, HDL,
on-HDL, and LDL between the 2 treatment arms (ator-
astatin vs. pravastatin). A chi-square test or Fisher exact
Abbreviations
and Acronyms
BMI  body mass index
CAC  coronary artery
calcium
CT  computed
tomography
CVS  calcium volume
score
EAT  epicardial adipose
tissue
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
Figure 1 Example of Epicardial Adipose Tissue
Extraction From Computed Tomography Images
Single axial image of the heart showing epicardial adipose tissue (gray filling)
between the orange lines. After applying an attenuation threshold of 190 to
30 Hounsfield units, all myocardial structures except for fat-containing voxels
are removed. The gray areas outside the orange lines and adjacent to the pari-
etal pericardium represent paracardial adipose tissue. The inset shows at what
level of the myocardium the axial slice was obtained.
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characteristics between the 2 treatment arms. A paired
Student t test was used to test the significance of the percent
hange from the pre- to post-treatment in CVS or EAT
ithin each treatment group. Analysis of variance or Pear-
on correlation coefficient was used to examine the relation-
hip of baseline EAT with total cholesterol, LDL, HDL,
on-HDL, triglycerides, body mass index (BMI), CVS,
ge, presence or absence of diabetes, hypertension, and
moking. Pearson correlation coefficients were estimated to
easure the relationship between the percent change in
AT with the percent change in total, LDL and non-HDL
Baseline Characteristics in the 2 Treatment GroupsTable 1 Baseline Characteristics in the 2 Treatment Groups
Characteristic
Atorvastatin
(n  194)
Pravastatin
(n  226) p Value
Age, yrs 64.5 (52.6–79.6) 65.4(50.3–77.7) 0.548*
BMI, kg/m2 27.6 (17.4–46.4) 28.2 (15.9–47.5) 0.194*
Race 0.224†
Asian 3 (1.55) 0 (0)
Black 10 (5.15) 8 (3.56)
Hispanic 6 (3.09) 6 (2.67)
Other 0 (0) 2 (0.89)
White 175 (90.21) 209 (92.89)
HRT 46 (23.7) 51 (22.6) 0.781‡
Hypertension 75 (38.7) 98 (43.4) 0.329‡
Diabetes 26 (13.4) 35 (15.5) 0.546‡
History of MI 5 (2.6) 4 (1.8) 0.738†
CABG 1 (0.5) 2 (0.9) 1.000†
Angina 14 (7.2) 15 (6.6) 0.815‡
PVD 11 (5.7) 18 (8.0) 0.355‡
Smoker 114 (58.8) 131 (58) 0.869‡
Cholesterol
Total 269 (148–395) 262 (147–470) 0.428*
LDL 174.5 (55–287) 171 (76–318) 0.333*
HDL 56 (28–110) 57 (32–103) 0.358*
Non-HDL 210 (70–337) 204 (105–436) 0.223*
TGs 164 (65–618) 157 (46–674) 0.419*
EAT volume 105.0 (34.9–271.6) 103.6 (39.5–307.4) 0.950*
CVS 136.2 (10.3–3,057.5) 173.3 (0–4,586.6) 0.071*
Values are median (range) or n (%). *p value is calculated by Wilcoxon rank sum test. †p value is
calculated by the Fisher exact test. ‡p value is calculated by the chi-square test.
BMI body mass index; CABG  coronary artery bypass grafting; CVS calcium volume score;
EAT  epicardial adipose tissue; HDL  high-density lipoprotein; HRT  hormone replacement
therapy; LDL  low-density lipoprotein; MI  myocardial infarction; PVD  peripheral vascular
disease; TGs  triglycerides.
Effect of Atorvastatin and Pravastatin on Lipid STable 2 Effect of Atorvastatin and Pravasta
Parameter Atorvastatin (n 
Percent change in TC 39.2 (57.9 to 1
Percent change in LDL 53.3 (69.4 to 2
Percent change in non-HDL 49.7 (65.7 to 1
Percent change in HDL 2.1 (33.3 to 4
Percent change in TG 28.2 (79.1 to 1
Percent change in CVS 12.1 (63.4 to 2
Percent change in EAT 3.38 (30.1 to 4Values are median (range). *p value is calculated by the Wilcoxon rank sum
CVS  calcium volume score; TC  total cholesterol; other abbreviations acholesterol, and triglycerides within the whole group, the
atorvastatin group, and pravastatin group. A general linear
model was used to estimate the adjusted relationship of the
percent change in EAT with the percent change in CVS,
non-HDL, triglycerides, and LDL in the whole group, the
atorvastatin group, and the pravastatin group after adjusting
for BMI and other variables. A logistic regression analysis
was used to identify the best independent predictors of a
minimum EAT change of 1% among the following vari-
ables: age, BMI, hypertension, diabetes mellitus, baseline
and change in serum levels of LDL and non-HDL choles-
terol. The significance level was set at 0.05 for all tests. The
SAS statistical package version 9.2 (SAS Institute, Inc.,
Cary, North Carolina) was used for data management and
analysis.
Results
Of the 420 patients, 194 received atorvastatin and 226
pravastatin. The clinical characteristics of the 2 groups are
presented in Table 1.
The median and range EAT volumes at baseline were not
different between the atorvastatin (105, 34.9 to 271.6 ml)
and pravastatin (103.6, 39.5 to 307.4 ml) groups (p 0.95);
t baseline, EAT was larger in hypertensive than in normo-
ensive patients (median and range: 113, 35 to 307 vs. 98, 36
o 272 ml; p  0.001) and in diabetic than in nondiabetic
atients (119, 71 to 248 ml vs. 102, 35 to 307 ml; p 
.001). EAT volume was weakly but significantly correlated
ith age (r 0.206), BMI (r 0.469), HDL (r0.239),
riglyceride levels (r  0.213), and CVS (r  0.214)
p  0.001 for all correlations).
At the end of follow-up (Table 2), the atorvastatin group
xperienced a greater percent decrease compared with the
ravastatin group in total cholesterol (median: 39.2% vs.
19.6%; p  0.001), LDL cholesterol (median: 53.3% vs.
28.3%; p 0.001), triglycerides (median,28.2% vs.13.6%;
 0.001), and non-HDL cholesterol (median: 49.7% vs.
25.5%; p 0.001) levels; there was a small HDL cholesterol
ncrease that was nonsignificantly different between treat-
ent groups (median: 2.1% atorvastatin vs. 4% pravastatin;
 0.18). At the end of treatment, the percent EAT
eduction was significantly greater in the atorvastatin-
Levels, CAC, and EATLipid Serum Levels, CAC, and EAT
Pravastatin (n  226) p Value
19.6 (42.6 to 43.5) 0.001*
28.3 (54.8 to 73.7) 0.001*
25.5 (53.0 to 50.5) 0.001*
4.0 (28.1 to 52.6) 0.181*
13.6 (73.4 to 135.8) 0.001*
12.7 (75.1 to 358.3) 0.45*
0.83 (37.9 to 62.8) 0.025*erumtin on
194)
5.7)
0.2)
5.4)
1.7)
57.7)
07.8)
0.1)test.
s in Table 1.
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(median: 3.38% vs. 0.83%; p  0.025, Table 2). The
ercent EAT change from baseline was significant in the
torvastatin (p 0.001), but not in the pravastatin (p 0.2)
roup. Identical results were obtained when using absolute
hange rather than relative change in EAT (data not
hown). Although the serum lipids were lowered signifi-
antly in both statin groups, there was no significant
orrelation between reduction in total, LDL, non-HDL
holesterol, triglycerides, and EAT reduction in either treat-
ent arm (Fig. 2). The CVS progressed significantly from
aseline in both treatment arms (p 0.001 for both treatment
rms from baseline; p  0.45 between groups) (Table 2).
The single best independent predictor of a minimum
AT change of 1% was the baseline non-HDL choles-
erol level (odds ratio: 0.991; 95% confidence interval: 0.985
o 0.996; p  0.002) in a model containing age, BMI,
ypertension, diabetes mellitus, and baseline and change in
erum levels of LDL and non-HDL cholesterol.
iscussion
e showed that intensive lipid-lowering therapy with
torvastatin for 1 year was associated with a significant
eduction in EAT volume in postmenopausal women. This
ffect was not observed in the group that received more
oderate statin treatment; the difference between the 2
reatment arms was significant. Even in the absence of a
ignificant regression from baseline, the pravastatin group
ay have benefitted from treatment. In fact, extrapolating
rom a previous publication (10), the average yearly EAT
ercent change approximated 3% in 249 subjects with stable
ody weight followed for 4 years. This is substantially
Figure 2 Correlation of EAT and LDL Change
Scatterplot of the percent change in epicardial adipose tissue (EAT) and low-densiarger than the 3% regression we observed in the
torvastatin-treated patients, but also larger than what we
bserved in the pravastatin-treated arm.
EAT has emerged as a novel marker of coronary athero-
clerosis risk; it has been associated with subclinical coro-
ary atherosclerosis, coronary obstructive disease (11), and
dverse cardiac events (12). It has been suggested that EAT
ay play a pathogenetic role in the inception and progres-
ion of coronary atherosclerosis through paracrine effects
nd by supporting local inflammatory activities (2,13,14).
f interest, EAT volume has been shown to be larger in
atients with coronary atherosclerotic lesions demonstrating
eatures of vulnerability such as low-density cores, positive
emodeling, and spotty calcification (4,5), and in patients
ith acute coronary syndromes (15).
Several primary and secondary prevention trials have dem-
nstrated the ability of statins to reduce cardiovascular events in
broad range of populations. Intensive lipid lowering with
tatins inhibited the progression of atherosclerotic plaques in
he REVERSAL (Reversal of Atherosclerosis with Aggressive
ipid Lowering Therapy) (16) and the ASTEROID (A Study
o Evaluate the Effect of Rosuvastatin on Intravascular
ltrasound-Derived Coronary Atheroma Burden) (17) trials;
urthermore, intensive statin therapy has been linked with a
reater reduction in cardiovascular events compared with
oderate lipid-lowering treatment (18). This has been
ttributed mainly to the larger cholesterol-lowering effect
chieved with intensive lipid-lowering treatment; however,
here is evidence that statins exert an anti-inflammatory
ffect that may play an important role in risk reduction
19,20). Of note, a greater reduction in CRP was found in
atients receiving atorvastatin compared with pravastatin in
rotein (LDL) for all patients showing no correlation between these 2 endpoints.ty lipop
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is evidence that epicardial visceral fat is a source of inflam-
matory mediators.
The current study was a subanalysis of the BELLES trial
designed to address the effect of aggressive versus moderate
statin therapy on CAC progression in post-menopausal
hyperlipidemic women. As reported in the original publi-
cation, intensive lipid-lowering therapy did not reduce
CAC progression compared with moderate lipid-lowering
therapy (7), an effect later confirmed in a study including
both men and women (21). These publications demon-
strated that sequential CAC imaging is the wrong surrogate
marker to assess the effectiveness of lipid-lowering thera-
pies. Indeed, a healing plaque may be accumulating calcium
to replace the lipid core (22,23).
In contrast, in these subanalyses of the BELLES trial, we
demonstrated that EAT can be reduced with intensive
statin therapy. The mechanisms involved in the observed
EAT regression are not known at this time and only
speculative considerations can be offered. In animal exper-
iments, statins have been shown to reduce inflammation in
the visceral adipose tissue as well as the arterial wall (24,25);
obese mice treated with statins exhibited a lower adipose
tissue mass (25). However, a short-term study of atorvasta-
tin therapy in patients with documented atherosclerosis did
not show an effect on visceral adipose tissue (26), whereas
weight loss was associated with a reduction in EAT in a
small patient sample (10). In the BELLES trial, body
weight and BMI were measured only at baseline; therefore,
we are unable to determine whether the measured change in
EAT volume was accompanied by a parallel decrease in
body weight. However, to our knowledge, there is currently
no evidence that statin use is associated with weight loss,
although such a question has been addressed in several
multicenter statin trials. Finally, in a recent publication,
Takase et al. (27) demonstrated a reduction in visceral
abdominal fat tissue after 6 months of treatment with
ezetimibe compared with placebo. The reduction was not
correlated with LDL lowering, as seen in our study, and
patients did not show any weight change while on treat-
ment. The reduction in visceral abdominal fat tissue was
also associated with an increase in adiponectin and was not
accompanied by a parallel reduction in subcutaneous fat.
Our findings may support the notion that atherosclerosis
is a perivascular disease rather than an intravascular phe-
nomenon (28–30). In fact, experimental evidence suggests
that lipids may be brought into the intima via the vasa
vasorum penetrating from the adventitia through the vessel
wall (27–29). Furthermore, recent research suggests that
intensive lipid-lowering therapy reduces the concentration
of vasa vasorum around the human carotid artery (31).
In the present study, we used noncontrast-enhanced
electron beam CT scans previously obtained to measure
CAC with a standardized protocol. EAT can be measured
easily on the same scans without adding unnecessary radi-
ation exposure, time, and cost for the patient. EAT can bemeasured on either noncontrast or contrast-enhanced car-
diac CT images, with very good reproducibility (32), and
our investigators demonstrated a high-degree of accuracy.
We used the term epicardial to denote all adipose tissue
surrounding the heart, but confined within the parietal
layer of the pericardium; this is in line with previous
publications from our research group (2,3,9,33) as well as
others (4,15,34,35).
Study limitations. The BELLES trial enrolled only post-
menopausal hyperlipidemic women, and our results do not
automatically extend to men and other populations with a
different risk profile. The original study was not designed to
measure EAT sequentially, and power calculations were
based on the expected change in CAC score over a year’s
time. Weight and BMI were measured only at baseline, and
although we have no repeat measurements, weight and BMI
never showed a significant change in any of the major statin
trials. We did not measure serum high-sensitivity C-reactive
protein or other inflammatory markers in our study population;
however, it is reasonable to expect a significant reduction in
high-sensitivity C-reactive protein with intensive lipid-
lowering therapy (36). Furthermore, even in the absence of
a systemic effect, the regional effect on adipose tissue would
be of greater interest, but this could only be tested with
pericardial biopsies that are obviously impractical. All pa-
tients enrolled in the BELLES trial were treated with 1 of
2 statins, and the absence of a placebo control prevented us
from assessing the natural history of EAT over time. The
fact that EAT is positively associated with age, however,
suggests that there is a natural tendency for EAT to increase
over time, and the negative trend shown by patients in both
treatment arms suggests an actual impact of active therapy
on this marker.
Conclusions
We demonstrated that intensive lipid-lowering therapy with
atorvastatin induced significant EAT regression in a suba-
nalysis of a large randomized clinical trial of hyperlipidemic
post-menopausal women; moderate-intensity lipid-
lowering therapy did not attain equal results. Although the
extent of EAT has been associated with the presence of
subclinical atherosclerosis and adverse outcomes, there is
currently no knowledge of the prognostic impact of EAT
regression or the extent of EAT regression that might be
linked with an improved outcome; future studies should
address this interesting question. EAT volume modulation
may be one of the unsuspected mechanisms whereby statins
influence a patient’s outcome. Due to its ease of measure-
ment, especially compared with intravascular imaging meth-
odologies, sequential EAT measurements may become a
useful method to assess the effectiveness of risk-reduction
therapies.
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